Key Points GAAP revenue beat expectations at $105.6 million for Q2 2025 but was down 37.4% year over year. GAAP earnings per share rose to $0.22 for Q2 2025, including a $2.0 million net-of-tax ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Adjusted EBITDA (Q4): Adjusted EBITDA loss of $316,000 for Q4 FY2025, substantially narrowed from a $1.7 million adjusted ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Learn more about the gut microbiome's digestion of the amino acid tryptophan, which creates byproducts with potential for ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

Once-weekly semaglutide significantly slowed epigenetic aging in adults with HIV-associated lipohypertrophy, as measured by ...

While GLP‑1 receptor agonists may be best known for aiding weight loss and regulating digestion, gastroenterologists are also drawing attention to the therapies’ effect on the brain. Indeed, recent ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions like obesity and type 2 diabetes, many lacked insurance or a routine place for ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S.